Overview

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Status:
Terminated

Trial end date:
2018-12-28

Target enrollment:

Participant gender:

Summary

This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Verastem, Inc.

Treatments:

Avelumab